Trial Profile

Dipeptidylpeptidase IV (CD26) on Philadelphia-positive leukemic stem cells (LSC) as marker and novel therapeutic target in chronic myeloid leukemia (CML)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 30 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nilotinib (Primary) ; Vildagliptin (Primary)
Indications Chronic myeloid leukaemia
Focus Adverse reactions; First in man; Therapeutic Use
Acronyms Dolphin-STAR

Most Recent Events

21 Jun 2020 Results (n=6) assessing safety and feasibility of vildagliptin in combination with nilotinib in patients with chronic myeloid leukemia, presented at the 25th Congress of the European Haematology Association.
05 Oct 2018 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com